



Jemperli (dostarlimab-gxly) – New indication

- On August 17, 2021, [GlaxoSmithKline](#) announced the [FDA approval](#) of [Jemperli \(dostarlimab-gxly\)](#), for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
- Jemperli is also approved for the for the treatment of adult patients with dMMR recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen.
- Both of Jemperli's indications are approved under accelerated approval based on tumor response rate and durability of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
- The approval of Jemperli for the new indication was based on GARNET, a non-randomized, open-label, multicohort study. The efficacy population consisted of a cohort of 209 patients with dMMR recurrent or advanced solid tumors who progressed following systemic therapy and had no satisfactory alternative treatment options. The major efficacy outcome measures were overall response rate (ORR) and duration of response (DOR).
 - The ORR was 41.6% (95% CI: 34.9, 48.6).
 - The median DOR was 34.7 months (range: 2.6, 35.8+).
- The recommended dose of Jemperli for both of its indications is:
 - Dose 1 through Dose 4: 500 mg every 3 weeks
 - Subsequent dosing beginning 3 weeks after Dose 4 (Dose 5 onwards): 1,000 mg every 6 week
 - Jemperli should be administered as an intravenous infusion over 30 minutes. Patients should be treated until disease progression or unacceptable toxicity.
- Patients should be selected for treatment with Jemperli based on the presence of dMMR in tumor specimens. Information on FDA-approved tests for the detection of dMMR status is available at <https://www.fda.gov/companiondiagnostics>.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.